Clinical Trials Logo
  1. Home
  2. Treatment Resistant Depression
  3. NCT01868802

Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population

Treatment-Resistant Depression Clinical Trial

Official title:
Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population

Clinical Trial Summary

A randomized multicentric parallel arms study involving the use of ketamine for treatment-resistant depression will be held at three national health provider clinics in the Mexican population. The purpose of this study is to determine whether clinical response seen in previous studies is replicable in this population.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01868802
Study type Interventional
Source American British Cowdray Medical Center
Contact Paul J Lamothe, M.D.
Phone +52 (55) 11031750
Email paul@lamothe.com
Status Recruiting
Phase Phase 2
Start date September 2013
View Details
See also
  Status Clinical Trial Phase
Completed NCT02497287 - A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression Phase 3
Recruiting NCT03653858 - Efficacy Study of Deep Brain Stimulation in Patients With Treatment Resistant Major Depression N/A
Recruiting NCT02462551 - Focal Electrically Administered Seizure Therapy for the Treatment of Depression N/A
Recruiting NCT05377177 - Cortical Inhibition as a Biomarker of Response in a Comparison of Bilateral Versus Unilateral Accelerated Theta Burst Stimulation for Suicidal Ideation in Treatment-Resistant Depression -COMBAT-SI N/A
Completed NCT05095792 - Effect of Ketamine on Neurological Activity as Measured by Electroencephalogram (EEG)
Recruiting NCT06372834 - Adjuvant Accelerated piTBS for Reducing Suicidal Ideation in TRD Patients: A Randomized, Sham-controlled Trial N/A
Active, not recruiting NCT03701724 - Cost-utility Analysis of Maintenance rTMS for Treatment-resistant Depression N/A
Recruiting NCT05800860 - A Trial of GH001 in Patients With Treatment-resistant Depression Phase 2
Completed NCT01945047 - Action of Ketamine in Treatment-Resistant Depression Phase 2/Phase 3
Recruiting NCT05045378 - Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression Phase 4
Completed NCT05454410 - Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD) Phase 2
Recruiting NCT05422417 - Dorsomedial Prefrontal Neuromodulation in Treatment-resistant Depression N/A
Recruiting NCT05842291 - pBFS Guided High-dose rTMS Therapy for Treatment-Resistant Depression N/A
Recruiting NCT04821271 - Antidepressant Effects of TS-161 in Treatment-Resistant Depression Phase 2
Active, not recruiting NCT04670081 - Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression Phase 2
Terminated NCT01598324 - Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder N/A
Recruiting NCT05710237 - Does Psilocybin Require Psychedelic Effects to Treat Depression? Phase 2
Completed NCT03329391 - Psychosocial Characteristics and Non-pharmacological Intervention of Patients With Treatment-resistant Depression N/A
Not yet recruiting NCT05661383 - Olfactory and Brain Stimulations in Treatment-resistant Depression N/A
Recruiting NCT05777876 - Early Identification of TRD and Construction and Clinical Validation of NTBS Precision Technology N/A